Zimmer Biomet Holdings, Inc. (SWX:ZBH)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 16.52B +17.7% |
| Revenue (ttm) | 7.15B +7.0% |
| Net Income | 640.27M -4.7% |
| EPS | 3.32 -2.0% |
| Shares Out | n/a |
| PE Ratio | 26.52 |
| Forward PE | 11.72 |
| Dividend | 0.78 (0.88%) |
| Ex-Dividend Date | Sep 30, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 88.00 |
| Day's Range | n/a |
| 52-Week Range | 62.50 - 88.00 |
| Beta | 1.01 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well a... [Read more]
Financial Performance
In 2025, Zimmer Biomet Holdings's revenue was $8.23 billion, an increase of 7.20% compared to the previous year's $7.68 billion. Earnings were $705.10 million, a decrease of -21.98%.
Financial numbers in USD Financial StatementsNews
Zimmer Biomet to Present at the Annual Jefferies Global Healthcare Conference in London
WARSAW, Ind., Nov. 9, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will ...
Zimmer Biomet price target raised to $115 from $100 at Barclays
Barclays raised the firm’s price target on Zimmer Biomet (ZBH) to $115 from $100 and keeps an Equal Weight rating on the shares. The company showed encouraging progress excluding knees…
Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery
New Category Will Introduce a Closed-Loop Framework: Predict. Perform. Recover.
Zimmer Biomet price target raised to $114 from $106 at Truist
Truist analyst Richard Newitter raised the firm’s price target on Zimmer Biomet (ZBH) to $114 from $106 and keeps a Hold rating on the shares. Q3 saw another quarter of…
Zimmer Biomet price target raised to $125 from $110 at RBC Capital
RBC Capital raised the firm’s price target on Zimmer Biomet (ZBH) to $125 from $110 and keeps an Outperform rating on the shares. The firm cites the company’s Q3 earnings…
Zimmer Biomet price target raised to $120 from $117 at JPMorgan
JPMorgan analyst Robbie Marcus raised the firm’s price target on Zimmer Biomet (ZBH) to $120 from $117 and keeps a Neutral rating on the shares.
Zimmer Biomet price target raised to $130 from $120 at UBS
UBS raised the firm’s price target on Zimmer Biomet (ZBH) to $130 from $120 and keeps a Buy rating on the shares.
Zimmer Biomet price target raised to $111 from $100 at Canaccord
Canaccord analyst Caitlin Cronin raised the firm’s price target on Zimmer Biomet (ZBH) to $111 from $100 and keeps a Hold rating on the shares. The firm said they delivered…
Zimmer Biomet price target raised to $125 from $110 at Stifel
Stifel raised the firm’s price target on Zimmer Biomet (ZBH) to $125 from $110 and keeps a Buy rating on the shares.
Zimmer Biomet price target raised to $114 from $104 at Baird
Baird raised the firm’s price target on Zimmer Biomet (ZBH) to $114 from $104 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results…
Zimmer Biomet price target raised to $117 from $99 at Citi
Citi raised the firm’s price target on Zimmer Biomet (ZBH) to $117 from $99 and keeps a Neutral rating on the shares.
Zimmer Biomet price target raised to $107 from $93 at Bernstein
Bernstein raised the firm’s price target on Zimmer Biomet (ZBH) to $107 from $93 and keeps a Market Perform rating on the shares. The firm notes the company reported solid…
Zimmer Biomet price target raised to $125 from $110 at RBC Capital
RBC Capital raised the firm’s price target on Zimmer Biomet (ZBH) to $125 from $110 and keeps an Outperform rating on the shares.
Zimmer Biomet Holdings Earnings Call Transcript: Q3 2026
Q3 sales grew 3.7% in constant currency, with broad strength across hips, S.E.T., and technology offsetting knee and China headwinds. Full-year sales and adjusted EPS guidance increased, while U.S. commercial investment and Monogram remain key execution priorities.
Zimmer Biomet Holdings Earnings release: Q3 2026
Zimmer Biomet Holdings released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Zimmer Biomet Holdings Quarterly report: Q3 2026
Zimmer Biomet Holdings has published its Q3 2026 quarterly earnings report on November 4, 2026.
Zimmer Biomet Announces Third Quarter 2026 Financial Results
Third quarter net sales of $2.063 billion increased 3.1% on a reported basis and 3.7% on a constant currency1 basis Third quarter diluted earnings per share were $1.00, a decrease of 13.8%; adjusted1 ...
Zimmer Biomet to Preview the Next Era of Intelligent Orthopedic Surgery at AAHKS 2026
Featured symposium will reveal a new vision for intelligent systems that support surgeon judgment, reduce procedural burden and connect the episode of care WARSAW, Ind., Oct. 29, 2026 /PRNewswire/ -- ...
3 of the Best Smaller-Cap Stocks to Own
These stocks of smaller companies with wide economic moats are good long-term buys when you can get them on sale.
Zimmer Biomet’s recent weakness offers a buying opportunity, says Argus
Argus analyst David Toung keeps a Buy rating and $125 price target on Zimmer Biomet (ZBH) but believes that the stock’s recent weakness offers a buying opportunity. The company has…
Zimmer Biomet and THINK Surgical extend exclusive distribution agreement
Zimmer Biomet (ZBH) and THINK Surgical, a company in the field of orthopedic surgical robots, announced a multi-year extension of its Limited Exclusive Distribution and Supply Agreement following a su...
ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT
Multi-Year Extension to Help Accelerate Adoption of Wireless, Handheld TMINI® System for Use with Zimmer Biomet's Persona® Knee System FREMONT, Calif. and WARSAW, Ind.
Zimmer Biomet initiated with an Equal Weight at Barclays
Barclays analyst Christopher Pasquale initiated coverage of Zimmer Biomet (ZBH) with an Equal Weight rating and $100 price target The firm rolled out coverage of the medical suppliers and devices…
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results
WARSAW, Ind., Oct. 6, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its third quarter earnings conference call will be webc...